STRYKER CORP

Stryker Corporation has a market capitalization of $121.8 billion and a price-to-earnings ratio of 37.52, indicating a premium valuation relative to earnings. The company's liquidity position is characterized by a current ratio of 1.89 and cash and equivalents of $4.01 billion, but net cash is negative after subtracting total debt. The company's profitability is reflected in a gross profit of $16.07 billion and an operating income of $4.89 billion, with a return on equity of 14.48%. These figures suggest strong profitability, although the debt-to-equity ratio of 0.66 indicates moderate leverage. Stryker's revenue is distributed across its MedSurg and Neurotechnology segment and Orthopaedics segment. The company's geographic exposure is primarily in the United States, with operations in other countries. The revenue concentration in the US suggests potential exposure to domestic market dynamics. The company's growth trajectory is supported by a revenue of $25.12 billion in FY2025. The outlook for the next fiscal year is positive, with a mean price target of $417.50 from analysts, indicating potential for growth. Risk factors include a medium liquidity risk and an unknown dilution risk. The company's capital structure includes long-term debt of $14.86 billion, which could impact its financial flexibility. Recent events include the acquisition of Inari and the sale of the Spinal Implants business. These transactions have implications for the company's strategic direction and financial position.